Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 STERIS
Historique des cours de bourse
Prix actuel de l'action	US$237.93
Plus haut sur 52 semaines	US$269.44
Plus bas sur 52 semaines	US$195.14
Bêta	0.91
Variation sur 1 mois	11.15%
Variation sur 3 mois	9.86%
Variation sur 1 an	-5.53%
Variation sur 3 ans	5.09%
Variation sur 5 ans	11.39%
Évolution depuis l'introduction en bourse	11,436.00%

Nouvelles et mises à jour récentes

Mise à jour du récit • Aug 09

STE: North Carolina Expansion And Dividend Growth Will Support Future Upside

Analysts have modestly raised their price target for STERIS to about $262 per share. This reflects updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E.

Recent updates

Mise à jour du récit • Aug 09

STE: North Carolina Expansion And Dividend Growth Will Support Future Upside

Analysts have modestly raised their price target for STERIS to about $262 per share. This reflects updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E.

Seeking Alpha • Jul 27

Steris: A Good Moment To Buy Shares In This Sterilization Leader

Summary Steris provides infection prevention products and sterilization services to medical clientele (such as hospitals, outpatient surgery centers, and pharmaceutical companies). Steris has increased its dividend for 21 consecutive years. The 10-year dividend growth rate of 9.6% is strong, but more recent dividend raises have actually been over 10%. STE has a great financial position. Its long-term debt/equity ratio is 0.3, while the interest coverage ratio is over 18. The P/E ratio is now down to 26.6. That’s far lower than its five-year average of 46.8. Read the full article on Seeking Alpha

Mise à jour du récit • Jun 24

STE: Share Repurchases And Recurring Platform Earnings Will Support Future Upside

Analysts have made a small adjustment to their price target on STERIS, keeping fair value around $256.86 while fine-tuning assumptions on discount rate, revenue growth, profit margin and future P/E to reflect updated expectations for the business. What's in the News STERIS reported fiscal 2026 adjusted EPS of $10.17 compared with $9.22 a year earlier and total revenue of $5.94b, with broad-based revenue growth led by healthcare and faster percentage gains in Life Sciences.

Mise à jour du récit • Jun 04

STE: Share Repurchases And Earnings Outlook Will Support Future Upside

Analysts have trimmed their price target for STERIS to $256.86 from $279.29, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that collectively point to a lower fair value estimate. What's in the News STERIS announced a share repurchase program authorizing the company to buy back up to US$1,000 million of its ordinary shares.

Mise à jour du récit • May 11

STE: Lower Discount Rate And Stable Assumptions Will Support Future Upside

Analysts have maintained their $279.29 price target for STERIS, supported by a slightly lower discount rate and minor adjustments to long-term revenue growth, profit margin, and future P/E assumptions. Valuation Changes Fair Value: Maintained at $279.29 per share, with no change in the updated analysis.

Mise à jour du récit • Apr 26

STE: Share Repurchases And Stable Assumptions Will Support Future Upside

Analysts have reiterated a $279.29 price target for STERIS, citing largely unchanged assumptions on growth, margins, discount rate and future P/E as the basis for maintaining their current valuation framework. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of its shares under an existing buyback program (Key Developments).

Mise à jour du récit • Apr 11

STE: Completed Buyback And Stable Assumptions Will Support Future Upside

Analysts kept their fair value estimate for STERIS steady at about $279 per share, while slightly updating assumptions around discount rate, revenue growth, profit margin, and future P/E. This reflects fine tuning of their models rather than a shift in the core outlook.

Mise à jour du récit • Mar 28

STE: Completed Buyback And Refined Assumptions Will Support Future Upside

Analysts have reduced their price target on STERIS by about $2 to reflect slightly updated assumptions for fair value, discount rate, revenue growth, profit margin, and forward P/E, while maintaining the overall thesis. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, accounting for 0.2% of its shares.

Article d’analyse • Mar 24

Is There Now An Opportunity In STERIS plc (NYSE:STE)?

STERIS plc ( NYSE:STE ) received a lot of attention from a substantial price movement on the NYSE over the last few...

Mise à jour du récit • Mar 11

STE: Completed Share Repurchases And Stable Assumptions Will Support Future Upside

Analysts have kept their STERIS price target steady at $281.25, with only minor tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock's valuation. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of shares.

Mise à jour du récit • Feb 25

STE: Completed Share Repurchases And Steady Assumptions Will Support Future Upside

Analysts have slightly trimmed their fair value estimate for STERIS to about $281 from roughly $282, reflecting modest tweaks to assumptions on the discount rate, long term revenue growth, profit margin, and future P/E expectations. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of its shares.

Mise à jour du récit • Feb 10

STE: Modest Assumption Tweaks Will Support A More Upbeat Fair View

Analysts have slightly adjusted their price target for STERIS to US$281.63, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E. Together, these factors suggest a modest recalibration of expectations rather than a major shift in outlook.

Mise à jour du récit • Jan 27

STE: Share Repurchases And Stable Outlook Will Support A Fair View

Analysts have kept their fair value estimate for STERIS steady at about $281.63 per share, while making only very small tweaks to assumptions such as the discount rate and future P/E, reflecting largely unchanged views on the company’s long term earnings power. What's in the News From July 1, 2025 to September 30, 2025, STERIS repurchased 400,000 shares, representing 0.41% of its shares, for $98.64 million under its existing buyback program (Key Developments).

Mise à jour du récit • Jan 10

STE: Share Repurchases And Steady Guidance Will Support A Fair Outlook

Analysts have kept their fair value estimate for STERIS essentially unchanged at about US$281.63, citing only very small tweaks to assumptions such as the discount rate, revenue growth, profit margin and future P/E that do not materially affect their overall price target view. What's in the News STERIS repurchased 400,000 shares from July 1, 2025 to September 30, 2025, representing 0.41% of shares for US$98.64 million, as part of its ongoing buyback program.

Article d’analyse • Jan 09

Here's Why STERIS (NYSE:STE) Has Caught The Eye Of Investors

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Article d’analyse • Dec 26

Earnings Tell The Story For STERIS plc (NYSE:STE)

With a price-to-earnings (or "P/E") ratio of 36.4x STERIS plc ( NYSE:STE ) may be sending very bearish signals at the...

Mise à jour du récit • Dec 23

STE: Share Repurchases And Steady Guidance Will Support A Fair Future Outlook

Analysts have modestly raised their price target on STERIS to $281.63, reflecting slightly higher long term growth and profitability expectations, despite largely unchanged model assumptions. What's in the News STERIS completed a share repurchase tranche between July 1 and September 30, 2025, buying back 400,000 shares, or 0.41% of shares outstanding, for $98.64 million (Key Developments).

Mise à jour du récit • Dec 09

STE: Modest Buybacks And Steady Guidance Will Support A Balanced Outlook

Analysts have modestly raised their price target on STERIS to approximately $282 per share from about $281.60, reflecting slightly lower perceived risk and a steady outlook for revenue growth, profit margins, and long term valuation multiples. What's in the News Completed a share repurchase program totaling 1,307,158 shares, or about 1.32% of shares outstanding, for $298.64 million under the buyback announced on May 3, 2023 (company filing).

Mise à jour du récit • Nov 25

STE: Stable Outlook And Share Buybacks Will Shape Near-Term Performance

Analysts have raised their price target for STERIS from $278.38 to $281.63. This change reflects modest expectations for improved revenue growth, even though there have been minor adjustments to other key financial metrics.

Mise à jour du récit • Nov 07

STE: Marginal Profit Margin Gains And Steady Outlook Will Influence Value

Analysts have raised their price target for STERIS from $272.38 to $278.38. They cite marginal improvements in projected profit margins, even though revenue growth expectations have been slightly reduced.

Article d’analyse • Oct 27

Is STERIS (NYSE:STE) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Mise à jour du récit • Sep 05

Healthcare Demand And Facility Expansion Will Create Value

With STERIS’s discount rate and future P/E both virtually unchanged, analyst valuation perspectives remain steady, resulting in an unchanged consensus price target of $272.38. What's in the News STERIS completed $200 million in share repurchases, totaling 907,158 shares (0.92%) under its current buyback program; no additional shares were repurchased in the latest quarter.

Article d’analyse • Aug 28

Calculating The Fair Value Of STERIS plc (NYSE:STE)

Key Insights STERIS' estimated fair value is US$227 based on 2 Stage Free Cash Flow to Equity With US$249 share price...

Seeking Alpha • Mar 22

Steris: AST Recovery Is Ongoing; Upgrading To 'Strong Buy'

Summary Upgraded Steris to 'strong buy' with a fair value of $254 per share due to strong recovery in its Applied Sterilization Technologies (AST) business. AST segment showed 9.5% organic growth, with management confident in further recovery despite challenges from rising labor costs and raw material inflation. For FY25, Steris guides for 6% revenue growth and 3.1% adjusted EPS growth, with significant contributions expected from Healthcare Products and AST segments. Key risks include weak capital equipment sales due to economic conditions, but overall, Steris's differentiated AST portfolio supports a positive long-term outlook. Read the full article on Seeking Alpha

Seeking Alpha • Nov 18

Steris Q2: Anticipating HSD Growth In AST, Upgrade To 'Buy'

Summary I am upgrading STERIS to a 'Buy' with a fair value of $240 per share due to the recent stock price pullback and solid growth prospects. STERIS reported 7.2% organic revenue growth and 5.4% adjusted EPS growth, with strong performance in the Applied Sterilization Technologies segment. Despite high interest rates, I anticipate a gradual recovery in the biotech industry, driving future double-digit revenue growth in STERIS' AST business. Key risks include potential legal liabilities from EtO emissions and weak near-term growth in healthcare capital equipment revenue. Read the full article on Seeking Alpha

Rendement pour les actionnaires

	STE	US Medical Equipment	US Marché
7D	2.0%	0.4%	-1.5%
1Y	-5.5%	-12.6%	17.8%

Rendement vs Industrie: STE a dépassé le secteur US Medical Equipment qui a rapporté -12.6 % au cours de l'année écoulée.

Rendement vs marché: STE a sous-performé le marché US qui a rapporté 17.8 % au cours de l'année écoulée.

Volatilité des prix

Is STE's price volatile compared to industry and market?
STE volatility
STE Average Weekly Movement	3.9%
Medical Equipment Industry Average Movement	8.5%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

Cours de l'action stable: STE n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.

Volatilité au fil du temps: La volatilité hebdomadaire de STE ( 4% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
1985	17,937	Dan Carestio	www.steris.com

STERIS plc fournit des produits et des services de prévention des infections aux États-Unis, en Irlande et dans le monde entier. Elle opère à travers trois segments : Healthcare, Applied Sterilization Technologies et Life Sciences. La société propose des produits chimiques de nettoyage et d'assurance de la stérilité, des systèmes automatisés de retraitement des endoscopes et des produits de suivi, des accessoires d'endoscopie, des instruments, des laveurs et des stérilisateurs et d'autres pièces d'équipement, ainsi que des équipements utilisés directement dans les salles d'intervention, notamment des tables chirurgicales, des éclairages, des services de gestion des équipements et des solutions de connectivité, ainsi que divers programmes de maintenance préventive, des services de réparation, des services de conseil en matière d'amélioration des processus personnalisés et des services externalisés de traitement stérile des instruments, ainsi que des services de réparation et de maintenance des instruments, des dispositifs et des endoscopes.

STERIS plc Résumé des fondamentaux

Comment les bénéfices et les revenus de STERIS se comparent-ils à sa capitalisation boursière ?
STE statistiques fondamentales
Capitalisation boursière	US$23.20b
Bénéfices(TTM)	US$805.00m
Recettes(TTM)	US$6.04b

28.8x

Ratio P/E

3.8x

Ratio P/S

Le site STE est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
STE compte de résultat (TTM)
Recettes	US$6.04b
Coût des recettes	US$3.36b
Marge brute	US$2.68b
Autres dépenses	US$1.88b
Les revenus	US$805.00m

Derniers bénéfices déclarés

Jun 30, 2026

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	8.26
Marge brute	44.42%
Marge bénéficiaire nette	13.33%
Ratio dettes/capitaux propres	26.2%

Quelles ont été les performances à long terme de STE?

Voir les performances historiques et les comparaisons

Dividendes

1.1%

Rendement actuel des dividendes

31%

Ratio de distribution

Le site STE verse-t-il des dividendes fiables ?

Voir STE l'historique des dividendes et les indices de référence

Quand faut-il acheter STE pour recevoir un dividende à venir ?
STERIS dates des dividendes
Date ex-dividende	Sep 04 2026
Date de paiement du dividende	Sep 25 2026
Jours jusqu'au dividende Ex	11 days
Jours jusqu'à la date de paiement du dividende	32 days

Le site STE verse-t-il des dividendes fiables ?

Voir STE l'historique des dividendes et les indices de référence

Analyse de l'entreprise et données financières

Données	Dernière mise à jour (heure UTC)
Analyse de l'entreprise	2026/08/23 15:02
Cours de l'action en fin de journée	2026/08/21 00:00
Les revenus	2026/06/30
Revenus annuels	2026/03/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

Paquet	Données	Cadre temporel	Exemple de source américaine ^*
Finances de l'entreprise	10 ans	Compte de résultat Tableau des flux de trésorerie Bilan	Formulaire 10-K de la SEC Formulaire 10-Q de la SEC
Estimations consensuelles des analystes	+3 ans	Prévisions financières Objectifs de prix des analystes	Rapports de recherche des analystes Blue Matrix
Prix du marché	30 ans	Cours des actions Dividendes, scissions et actions	Données de marché ICE Formulaire S-1 de la SEC
Propriété	10 ans	Actionnaires principaux Délits d'initiés	Formulaire 4 de la SEC Formulaire 13D de la SEC
Gestion	10 ans	L'équipe dirigeante Conseil d'administration	Formulaire 10-K de la SEC Formulaire SEC DEF 14A
Principaux développements	10 ans	Annonces de l'entreprise	Formulaire 8-K de la SEC

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés^.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

STERIS plc est couverte par 17 analystes. 9 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

Analyste	Institution
Michael Polark	Baird
Erin Wilson Wright	BofA Global Research
David Turkaly	Citizens JMP Securities, LLC

STERIS (STE) Aperçu de l'action

Récompenses

Analyse des risques

Analyst Price Targets

Healthcare Demand And Facility Expansion Will Create Value

Top Analyst Narratives

Healthcare Demand And Facility Expansion Will Create Value

STERIS plc Concurrents

Zimmer Biomet Holdings

ResMed

DexCom

GE HealthCare Technologies

Historique des prix et performances

Nouvelles et mises à jour récentes

Independent Chairman of the Board notifies of intention to sell stock

Independent Chairman of the Board notifies of intention to sell stock

STE: North Carolina Expansion And Dividend Growth Will Support Future Upside

First quarter 2027 earnings: EPS exceeds analyst expectations

Steris plc Appoints Pierre Boulud to the Audit Committee and the Compliance and Technology Committee

STERIS Unveils $600 Million Chemistries Center Plan for North Carolina Expansion

Recent updates

Independent Chairman of the Board notifies of intention to sell stock

Independent Chairman of the Board notifies of intention to sell stock

STE: North Carolina Expansion And Dividend Growth Will Support Future Upside

First quarter 2027 earnings: EPS exceeds analyst expectations

Steris plc Appoints Pierre Boulud to the Audit Committee and the Compliance and Technology Committee

STERIS Unveils $600 Million Chemistries Center Plan for North Carolina Expansion

STERIS plc Reiterates Earnings Guidance for Fiscal Year 2027

Fourth quarter dividend increased to US$0.69

Steris plc Raises Quarterly Interim Dividend, Payable on September 25, 2026

STERIS plc to Report Q1, 2027 Results on Aug 05, 2026

Steris: A Good Moment To Buy Shares In This Sterilization Leader

STE: Share Repurchases And Recurring Platform Earnings Will Support Future Upside

STERIS plc, Annual General Meeting, Jul 31, 2026

President recently sold US$947k worth of stock

STE: Share Repurchases And Earnings Outlook Will Support Future Upside

Upcoming dividend of US$0.63 per share

STERIS Sets Record Results With 9% Growth and US$1 Billion Buyback Target

Price target decreased by 8.0% to US$257

Full year 2026 earnings: EPS misses analyst expectations

STERIS plc Provides Earnings Guidance for the Fiscal Year Ended March 31, 2027

STE: Lower Discount Rate And Stable Assumptions Will Support Future Upside

Third quarter dividend of US$0.63 announced

STERIS plc Appoints Pierre Boulud to Board of Directors, Effective May 5, 2026

STERIS plc announces Quarterly dividend, payable on June 26, 2026

STE: Share Repurchases And Stable Assumptions Will Support Future Upside

STERIS plc to Report Q4, 2026 Results on May 11, 2026

STE: Completed Buyback And Stable Assumptions Will Support Future Upside

STE: Completed Buyback And Refined Assumptions Will Support Future Upside

Is There Now An Opportunity In STERIS plc (NYSE:STE)?

STE: Completed Share Repurchases And Stable Assumptions Will Support Future Upside

STE: Completed Share Repurchases And Steady Assumptions Will Support Future Upside

STE: Modest Assumption Tweaks Will Support A More Upbeat Fair View

Third quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter dividend of US$0.63 announced

STERIS plc Announces Quarterly Dividend, Payable on March 19, 2026

STE: Share Repurchases And Stable Outlook Will Support A Fair View

STERIS plc to Report Q3, 2026 Results on Feb 04, 2026

STE: Share Repurchases And Steady Guidance Will Support A Fair Outlook

Here's Why STERIS (NYSE:STE) Has Caught The Eye Of Investors

Earnings Tell The Story For STERIS plc (NYSE:STE)

STE: Share Repurchases And Steady Guidance Will Support A Fair Future Outlook

STE: Modest Buybacks And Steady Guidance Will Support A Balanced Outlook

STE: Stable Outlook And Share Buybacks Will Shape Near-Term Performance

Senior VP & GM of Life Sciences notifies of intention to sell stock

Senior VP notifies of intention to sell stock

STE: Marginal Profit Margin Gains And Steady Outlook Will Influence Value

Second quarter 2026 earnings: EPS and revenues exceed analyst expectations

STERIS plc Maintains Earnings Guidance for Fiscal Year 2026

First quarter dividend of US$0.63 announced

STERIS plc Declares Quarterly Dividend, Payable on December 18, 2025

Is STERIS (NYSE:STE) A Risky Investment?

STERIS plc to Report Q2, 2026 Results on Nov 05, 2025

Healthcare Demand And Facility Expansion Will Create Value

Calculating The Fair Value Of STERIS plc (NYSE:STE)

Upcoming dividend of US$0.63 per share

VP & Chief Accounting Officer notifies of intention to sell stock

First quarter 2026 earnings: EPS and revenues exceed analyst expectations

STERIS Announces Executive Changes, Effective from August 18, 2025

Fourth quarter dividend increased to US$0.63